Normalised Returns
Medical Equipment & Supplies · closest in market valuePOLYMED−10.8%Nifty Pharma+25.7%
Full Comparison
NSE filings · last close| Company | Price | Mkt Cap | P/E | P/B | ROE | Margin | Rev YoY | PAT YoY | D/E | 1Y Rtn |
|---|---|---|---|---|---|---|---|---|---|---|
| POLYMED ● | ₹1,724 | ₹17,478 Cr | 55.9× | 5.63× | 10.9% | 17.1% | +30.3% | −8.4% | 0.11× | −10.8% |
| MOLBIO | ₹1,246 | ₹15,101 Cr | – | – | – | – | – | – | – | – |
| FISCHER | ₹34.29 | ₹2,244 Cr | 75.3× | 5.82× | 8.0% | 10.1% | +249.4% | −24.3% | 0.19× | −68.9% |
| TARSONS | ₹332.75 | ₹1,770 Cr | 159.6× | 2.79× | 2.3% | 3.4% | +20.7% | −181.0% | 0.60× | +8.2% |
| LAXMIDENTL | ₹199.07 | ₹1,094 Cr | 35.4× | 4.50× | 12.8% | 10.4% | +13.9% | +23.8% | 0.00× | −37.6% |
| FABTECH | ₹145.83 | ₹648 Cr | 15.2× | 1.54× | 9.1% | 9.3% | +10.3% | +168.7% | 0.10× | −20.0% |
Medical Equipment & Supplies: the companies closest in market value, of the 7 in that basic industry whose filings we hold, from each company's NSE filings and the last close. Quarterly figures are for Q1 FY27; ROE, margin for FY26; P/B and D/E on the latest balance sheet. Green and red mark the two ends of a column; valuation and leverage columns are left plain. Hover a heading for its definition.
Against Medical Equipment & Supplies7 companies
P/E55.9×
15.5×median 59.4× · 4 of 6, highest first161.2×
P/B5.64×
1.58×median 3.62× · 2 of 6, highest first5.94×
ROE10.1%
1.7%median 8.9% · 3 of 6, highest first12.7%
Net margin15.7%
2.5%median 8.4% · 1 of 6, highest first15.7%
Revenue growth18.3%
10.6%median 18.3% · 2 of 3, highest first51.6%
Profit growth-12.5%
too few companies in the group report this to compare
Debt / equity0.11×
0.00×median 0.11× · 3 of 6, highest first0.60×
Dividend yield0.2%
0.1%median 0.2% · 2 of 3, highest first0.4%
1-year price change-15.1%
-70.4%median -15.1% · 3 of 5, highest first51.9%
Everyone in Medical Equipment & Supplies whose filings we hold: 7 companies, its basic industry within Healthcare. Figures as the screener works them out (the last four quarters' profit, the latest balance sheet, the last close), so ROE can differ a little from the Financials tab's latest-year figure. A place in the line is a fact about a number, not a view on the company.
POLYMED Rankings
Among 6 companies compared
Profitability
2
ROE 10.9%2nd highest of 51
Net margin 17.1%Highest of 5Growth
2
Revenue YoY +30.3%2nd highest of 53
Net profit YoY −8.4%3rd highest of 5Leverage
3
Debt / equity 0.11×3rd lowest of 5Valuation
3
P/E 55.9×3rd lowest of 54
P/Book 5.63×4th lowest of 5Price
2
1-year return −10.8%2nd highest of 5Position 1 is the lowest NPA, multiple or leverage, and the highest return, growth or profitability figure. These are positions among the companies listed here, not a view on the stock.